Health and Healthcare
Penwest Pharmaceuticals (PPCO) Set For Huge Fall
Published:
According to The Associated Press Endo Pharmaceuticals (ENDP). and Penwest Pharmaceuticals (PPCO). said Wednesday the patent on their pain drug Opana ER is being challenged by Impax Laboratories Inc.
Endo and Penwest are currently reviewing the details of this notice from IMPAX. Endo and Penwest note that they intend to pursue all available legal and regulatory avenues in defense of OPANA® ER, including enforcement of their intellectual property rights and approved labeling.
PPCO is off 31% in the pre-market at a 52-week low of $7.85.
Douglas A. McIntyre
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
